ANIK
Income statement / Annual
Last year (2023), Anika Therapeutics, Inc.'s total revenue was $166.66 M,
an increase of 6.67% from the previous year.
In 2023, Anika Therapeutics, Inc.'s net income was -$82.67 M.
See Anika Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$166.66 M |
$156.24 M |
$147.79 M |
$130.46 M |
$114.61 M |
$105.56 M |
$113.42 M |
$103.38 M |
$93.00 M |
$105.59 M |
| Cost of Revenue |
$63.57 M
|
$62.66 M
|
$64.85 M
|
$61.43 M
|
$28.75 M
|
$31.28 M
|
$27.36 M
|
$24.03 M
|
$21.05 M
|
$20.93 M
|
| Gross Profit |
$103.09 M
|
$93.58 M
|
$82.94 M
|
$69.03 M
|
$85.86 M
|
$74.28 M
|
$86.06 M
|
$79.35 M
|
$71.95 M
|
$84.66 M
|
| Gross Profit Ratio |
0.62
|
0.6
|
0.56
|
0.53
|
0.75
|
0.7
|
0.76
|
0.77
|
0.77
|
0.8
|
| Research and Development Expenses |
$32.69 M
|
$28.18 M
|
$27.33 M
|
$23.43 M
|
$16.67 M
|
$18.19 M
|
$18.79 M
|
$10.73 M
|
$8.99 M
|
$8.14 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$34.34 M
|
$21.54 M
|
$18.01 M
|
$14.83 M
|
$15.07 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$95.85 M
|
$84.79 M
|
$74.10 M
|
$60.06 M
|
$34.95 M
|
$34.34 M
|
$21.54 M
|
$18.01 M
|
$14.83 M
|
$15.07 M
|
| Other Expenses |
$62.19 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$191.48 M
|
$112.98 M
|
$101.42 M
|
$83.49 M
|
$51.62 M
|
$52.53 M
|
$40.33 M
|
$28.75 M
|
$23.81 M
|
$23.22 M
|
| Cost And Expenses |
$254.30 M
|
$175.64 M
|
$166.27 M
|
$144.93 M
|
$80.36 M
|
$83.81 M
|
$67.69 M
|
$52.77 M
|
$44.87 M
|
$44.15 M
|
| Interest Income |
$0.00
|
$654,000.00
|
$188,000.00
|
$498,000.00
|
$1.87 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$654,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$14.22 M
|
$16.35 M
|
$15.99 M
|
$15.00 M
|
$7.17 M
|
$5.91 M
|
$4.29 M
|
$3.73 M
|
$3.78 M
|
$4.71 M
|
| EBITDA |
-$11.23 M |
-$4.91 M |
$2.62 M |
-$12.83 M |
$34.25 M |
$27.66 M |
$50.02 M |
$54.34 M |
$51.91 M |
$61.45 M |
| EBITDA Ratio |
-0.07
|
-0.12
|
-0.27
|
-0
|
0.3
|
0.21
|
0.4
|
0.49
|
0.52
|
0.58
|
| Operating Income Ratio |
-0.53
|
-0.12
|
-0.13
|
-0.11
|
0.3
|
0.21
|
0.4
|
0.49
|
0.52
|
0.58
|
| Total Other Income/Expenses Net |
$2.31 M
|
$654,000.00
|
-$188,000.00
|
-$302,000.00
|
$1.87 M
|
$1.46 M
|
$473,000.00
|
$263,000.00
|
$120,000.00
|
$58,137.00
|
| Income Before Tax |
-$85.33 M
|
-$18.75 M
|
$2.43 M
|
-$28.62 M
|
$36.12 M
|
$23.21 M
|
$46.20 M
|
$50.87 M
|
$48.25 M
|
$61.51 M
|
| Income Before Tax Ratio |
-0.51
|
-0.12
|
0.02
|
-0.22
|
0.32
|
0.22
|
0.41
|
0.49
|
0.52
|
0.58
|
| Income Tax Expense |
-$2.66 M
|
-$3.89 M
|
-$1.71 M
|
-$4.64 M
|
$8.93 M
|
$4.49 M
|
$14.39 M
|
$18.32 M
|
$17.50 M
|
$23.19 M
|
| Net Income |
-$82.67 M
|
-$14.86 M
|
$4.13 M
|
-$23.98 M
|
$27.19 M
|
$18.72 M
|
$31.82 M
|
$32.55 M
|
$30.76 M
|
$38.32 M
|
| Net Income Ratio |
-0.5
|
-0.1
|
0.03
|
-0.18
|
0.24
|
0.18
|
0.28
|
0.31
|
0.33
|
0.36
|
| EPS |
-5.64 |
-1.02 |
0.29 |
-1.69 |
1.93 |
1.3 |
2.18 |
2.22 |
2.06 |
2.61 |
| EPS Diluted |
-5.64 |
-1.02 |
0.28 |
-1.69 |
1.89 |
1.27 |
2.11 |
2.15 |
2.01 |
2.51 |
| Weighted Average Shares Out |
$14.66 M
|
$14.56 M
|
$14.40 M
|
$14.22 M
|
$14.12 M
|
$14.44 M
|
$14.58 M
|
$14.68 M
|
$14.93 M
|
$14.68 M
|
| Weighted Average Shares Out Diluted |
$14.66 M
|
$14.56 M
|
$14.63 M
|
$14.22 M
|
$14.37 M
|
$14.69 M
|
$15.07 M
|
$15.12 M
|
$15.32 M
|
$15.27 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
